Short and mid-term outcomes of lung transplant recipients with COVID-19

Conclusions: We found a higher mortality and more severe disease course in LTX than in the healthy population. Recurrence of COVID-19 is a frequent event. At mid-term, we did not observe significant new incidence of CLAD onset. Treatment of COVID-19 and risk of CLAD after COVID-19 in LTX require further studies.

Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Happaerts, S., Lorent, N., Yserbyt, J., Dupont, L. J., Dooms, C., Van Bleyenbergh, P., Vanaudenaerde, B. M., Verleden, S. E., Ceulemans, L. J., Van Raemdonck, D. E., Verleden, G. M., Vos, R., Godinas, L. Tags: Transplantation Source Type: research